phrykt

Corvus Pharmaceuticals, Inc. (CRVS): who owns it and who trades it

As of Nov 16, 2026, CRVS insiders reported 7 purchases worth $384K in the last 12 months. The largest buyer was David Scott Moore (Director), with $250K. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Corvus Pharmaceuticals

From the latest filings

Overall: more buying than selling. Funds, insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CRVS

173 funds and institutions reported CRVS shares worth $1.1B at the end of Q2 2026, about 84% of the company. The largest holder is Orbimed Advisors LLC with 8.5%.

Funds and institutions (13F) 84%Everyone else 16%

10 largest owners, by share of the company

Orbimed Advisors LLC8.5%
BlackRock, Inc.8.5%
State Street Corp5.3%
T. Rowe Price Associates4.5%
Vanguard Capital Management LLC3.9%
Adams Street Partners LLC3.9%
Vivo Capital, LLC3.3%
Wellington Management Group LLP3.3%
Perceptive Advisors LLC3.2%
Deep Track Capital, LP3.0%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Orbimed Advisors LLC7.17M8.53%$107MNo change
BlackRock, Inc.7.14M8.50%$107M+16%
State Street Corp4.47M5.33%$66.8M+25%
T. Rowe Price Associates3.79M4.51%$56.6M+30%
Vanguard Capital Management LLC3.29M3.92%$49.2M+2%
Adams Street Partners LLC3.28M3.90%$48.9MNo change
Vivo Capital, LLC2.81M3.34%$41.9MNo change
Wellington Management Group LLP2.73M3.25%$40.8M+18%
Perceptive Advisors LLC2.67M3.18%$39.9M+16%
Deep Track Capital, LP2.49M2.97%$37.2MNo change
Braidwell LP2.13M2.53%$31.8M+21%
Geode Capital Management, LLC1.85M2.21%$27.7M+8%
Foresite Capital Management VI LLC1.83M2.18%$27.4MNo change
Goldman Sachs Group Inc1.58M1.88%$23.6M+2%
Hood River Capital Management LLC1.57M1.87%$23.5M+18%
Morgan Stanley1.34M1.60%$20.1M-46%
Boxer Capital Management, LLC1.10M1.31%$16.4MNo change
Catalio Capital Management, LP1.08M1.29%$16.1M+21%
Millennium Management LLC1.05M1.25%$15.7M+21%
Vanguard Portfolio Management LLC814,7500.97%$12.2M+22%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, CRVS insiders reported $384K of open-market purchases and $0 of sales.

Purchases, 12 months
$384K
7 trades, 3 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Nov 13, 2026
Filed Nov 13, 2026

Purchases and sales by month

$250K$250KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 13, 2026Jeffrey ArcaraChief Business OfficerPurchase503$10.37$5.2KForm 4
Nov 13, 2026Jeffrey ArcaraChief Business OfficerPurchase500$10.71$5.4KForm 4
Nov 12, 2026Jeffrey ArcaraChief Business OfficerPurchase497$11.12$5.5KForm 4
Nov 11, 2026Jeffrey ArcaraChief Business OfficerPurchase3,000$11.46$34.4KForm 4
Jun 11, 2026David Scott MooreDirectorPurchase21,700$11.53$250KForm 4
May 18, 2026Richard A Md MillerCEOPurchase5,000$12.05$60.2KForm 4
May 18, 2026Richard A Md MillerCEOPurchase1,932$12.01$23.2KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
David Scott MooreDirector$250K–Jun 11, 2026
Richard A Md MillerPresident and CEO, Director$83.5K–May 18, 2026
Jeffrey ArcaraChief Business Officer$50.5K–Nov 13, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CRVS short interest

Very high short interest. 21.1% of CRVS shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went down 6%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 17.76M CRVS shares were sold short, 21.1% of the shares outstanding, down 1.2% from the report before. At the average daily volume of 942,325 shares, buying them all back would take about 18.9 trading days (days to cover).

Shares short, % of all shares

21.1%May 15Oct 3023.1%

Days to cover

18.9May 15Oct 3032.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202617.76M21.11%-1%942,32518.9
Oct 15, 202617.97M21.36%+1%1.20M14.9
Sep 30, 202617.80M21.16%+4%1.34M13.3
Sep 15, 202617.18M20.42%-10%946,30718.2
Aug 31, 202619.02M22.61%-1%641,67029.6
Aug 14, 202619.13M22.74%+4%849,10522.5
Jul 31, 202618.31M21.80%+1%813,94422.5
Jul 15, 202618.06M21.50%-4%1.43M12.6
Jun 30, 202618.82M22.41%+5%1.52M12.4
Jun 15, 202617.88M21.29%+3%1.24M14.4
May 29, 202617.32M20.63%-8%2.05M8.4
May 15, 202618.91M22.51%+3%1.58M12.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Corvus Pharmaceuticals company events

Corvus Pharmaceuticals filed 12 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Aug 6, 2026ResultsReleased financial results. Filing
  3. Jul 22, 2026LeadershipIan T. Clark delivered notice of his intention to resign from the board of directors of Corvus Pharmaceuticals, Inc., effective as of July 22, 2026. Filing
  4. Jun 12, 2026VoteReported shareholder vote results. Filing
  5. May 14, 2026AnnouncementThe trial enrolled 72 patients with moderate-to-severe atopic dermatitis that previously failed one prior topical or systemic therapy. Filing
  6. May 7, 2026ResultsReleased financial results. Filing
  7. Apr 23, 2026LeadershipThe Board of Directors of Corvus Pharmaceuticals, Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Andrew C. Chan, M.D., Ph.D., to the Board, effective April 23, 2026. Filing
  8. Mar 13, 2026AgreementThe Company entered into an Amended and Restated Open Market Sale Agreement SM, with Jefferies LLC, to sell shares of the Company’s common stock, par value $0.0001 per share, from time to time through Jefferies acting as sales agent, having a maximum aggregate offering price of up to $200 million. Filing
  9. Mar 12, 2026ResultsReleased financial results. Filing
  10. Jan 23, 2026AnnouncementCorvus Pharmaceuticals, Inc. entered into an underwriting agreement with Jefferies LLC and Goldman Sachs & Co. LLC, as representatives of the several underwriters named therein, relating to the sale and issuance in an underwritten public offering by the Company of 7,900,677 shares of its common… Filing
  11. Jan 20, 2026AnnouncementIn connection with the proposed registered underwritten public offering, Corvus Pharmaceuticals, Inc. notified Jefferies LLC that it has suspended the offering of any shares of its common stock, par value $0.0001 per share, pursuant to the prospectus supplement filed with the Securities and… Filing
  12. Jan 20, 2026AnnouncementBased on the encouraging results from cohorts 1-3, cohort 4 was prospectively designed to support and potentially extend the clinical results obtained in the initial cohorts. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Corvus Pharmaceuticals financials

Famous investors that hold CRVS

5 of the 50 well-known investors we track reported holding CRVS in their latest 13F filing. The largest position is Ken Fisher's, worth $12M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Fisher · Fisher Asset ManagementQ3 20261.04M$12M0.0%New
Israel Englander · Millennium ManagementQ3 2026605,644$7M0.0%-42%
Steve Cohen · Point72 Asset ManagementQ3 2026435,146$5M0.0%New
Ken Griffin · Citadel AdvisorsQ3 2026399,918$4.6M0.0%+0%
Paul Tudor Jones · Tudor Investment CorpQ3 202648,984$564K0.0%+123%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named CRVS in the last 120 days.

FiledHolderFormStake
Nov 10, 2026STATE STREET CORPORATION13G4.0%
Nov 10, 2026STATE STREET CORPORATION13G4.0%

Questions about Corvus Pharmaceuticals, Inc. (CRVS) stock

Who owns the most CRVS stock?

The largest reported owner of Corvus Pharmaceuticals, Inc. (CRVS) is Orbimed Advisors LLC, with 8.5% of the company. In total, 173 funds and institutions reported holding CRVS at the end of Q2 2026, together about 84% of the shares. See the largest owners.

Are CRVS insiders buying or selling?

In the last 12 months, CRVS insiders reported 7 open-market purchases worth $384K and no sales. The latest trade was on Nov 13, 2026. See every trade.

What is the short interest in CRVS?

As of Oct 30, 2026, 17.76M CRVS shares were sold short, 21.1% of the shares outstanding, down 1.2% from the report before. At the average daily volume of 942,325 shares, buying them all back would take about 18.9 trading days (days to cover). See the history.

Which famous investors hold CRVS?

5 of the 50 well-known investors we track reported CRVS in their latest 13F filing, including Ken Fisher, Israel Englander, Steve Cohen. The largest position is worth $12M. See all holders.

Executive pay

Corvus Pharmaceuticals's chief executive was paid a total of $7M for the year ended Dec 31, 2025, up 129% from $3.1M the year before. In the last 12 months, Corvus Pharmaceuticals's executives and directors bought $384K of stock on the open market and sold none.

Chief executive, total pay$7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$7.3MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$3.2MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.